CureVac

On World Population Day, we reflect on the critical importance of addressing the health needs of our growing global population. With over 8 billion people on our planet, the challenge to provide equitable healthcare is greater than ever. At CureVac, we are dedicated to leveraging cutting-edge mRNA technology to develop innovative vaccines and therapeutics to advance human health. The idea of a healthier future for all people across the world is something that guides us every day in our work. We’re proud to be part of a larger ecosystem of innovators breaking through to new frontiers in medicine that will get us closer to this vision. Learn more about World Population Day: https://lnkd.in/dFFePXn #WorldPopulationDay #CureVac #HealthcareInnovation #SustainableDevelopment #mRNATechnology #GlobalHealth

🌐 Update on Trial Dates from CureVac! 🌐 CureVac is making strides in the mission to revolutionize medicine with mRNA technology. Today, we announced new trial dates for our ongoing patent litigation against Pfizer/BioNTech in the U.S., alongside related proceedings in Germany and the UK. Read the full Press Release here: https://lnkd.in/dbbmSgvD #CureVac #mRNA #Biopharmaceuticals #Innovation #PatentLitigation #BiotechNews

🚀New Licensing Agreement! 🚀 We're excited to announce today that CureVac has entered into a new licensing agreement with our long-time partner, GSK. Under this agreement, GSK will take over and obtain all developing, manufacturing and marketing rights for COVID-19 and flu vaccine candidates, including COVID/flu combinations. In return, CureVac will receive substantial upfront and milestone payments as well as tiered royalties, supporting us to move onto our next chapter and focus on what we do best – pushing the boundaries of what’s possible with mRNA innovation. While we unfortunately had to make the tough decision, also announced today, to trim our workforce as we enter this next era of the company, it will ultimately make CureVac stronger and put us in a better position to continue to innovate in the future and be a lasting force in the mRNA field. Please find the licensing agreement press release here: https://lnkd.in/ecz8Jx49 Please find the restructuring press release here: https://lnkd.in/e6ntMN7E   #CureVac #GSK #VaccineDevelopment #Innovation #Healthcare #ResearchAndDevelopment #Biotech #CureVac2.0

📢 Our CEO Alexander Zehnder, MD, MBA is featured in the latest issue of Drug Discovery World Summer 2024! 📢 Starting on page 46, he shares insights on the cutting-edge advancements in the field of mRNA and its impact on drug discovery. Don't miss out on this in-depth discussion on how these innovations could potentially shape the future of personalized medicine. Read the full article here: https://lnkd.in/gtSZijU9 #CureVac #DDWSummer2024 #DrugDiscovery #PersonalizedMedicine

We are eager to share insights on the latest advancements in cancer vaccines! Our Chief Scientific Officer, Dr. Myriam Mendila , has contributed her expert opinion on this crucial topic. Check out her thoughts and the broader discussion on how mRNA-based cancer vaccines could potentially activate the immune system in the article of The Medicine Maker. Don't miss this essential read! Read more: https://lnkd.in/eKVD-qY6 #CureVac #CancerResearch #CancerVaccines #Immunotherapy #CSO #MyriamMendila #TheMedicineMaker

🌟 Meet Manuel Göpferich, Bioinformatician-Data Engineer from CureVac, at The European mRNA Conference 2024 in Frankfurt! 🌟 Manuel will be discussing the Design of Optimised UTR Sequences Using Support Vector Machines. This event is a great opportunity to learn from industry experts and provide insights into the innovative work happening at CureVac. Join him and others: https://lnkd.in/eQyVemY9 #CureVac #mRNA #PharmaInnovation #PharmaEvents #Biotechnology #Healthcare

Today, we successfully held our Annual General Meeting in the beautiful city of Amsterdam. We reflected on 2023 as a year of remarkable achievements and shared insights into our latest developments. We are also excited to introduce Birgit Hofmann as a new member of the supervisory board. Welcome to CureVac, Birgit! Thank you to all our investors for your trust and support. Also thank you everyone who made this event a success! Together, we are shaping the future of healthcare. #CureVac #AGM #Amsterdam #Biotech #Innovation #Healthcare

Celebrating Pride Month at CureVac: Embracing Diversity and Inclusion! 🌈 June is Pride Month, and we at CureVac are proud to support the LGBTQ+ community. Diversity and inclusion are at the core of our company values, and we believe that a diverse and inclusive workplace is essential for innovation and success. Our strength lies in the uniqueness of our RNA people, and we are committed to fostering an environment where everyone can thrive. This Pride Month, we celebrate the vibrant and diverse voices that make CureVac a special place to work. #PrideMonth #DiversityAndInclusion #CureVacCares

🌟 Back-to-back excitement awaits as we gear up for the Goldman Sachs 45th Annual Global Healthcare Conference in Miami today! 🌟 Join us for another round of insightful discussions and networking opportunities alongside industry stalwarts and investment enthusiasts. Our team, including our new Chief Business Officer Thaminda Ramanayake, CEO Alexander Zehnder, MD, MBA and Dr. Sarah Fakih, MBA, Vice President Corporate Communications and Investor Relations, will be there to represent CureVac once again.

We are delighted to share that we will be participating in the 2024 Annual Congress of the European Association for Cancer Research (EACR), which will take place from June 10-13 in Rotterdam. This prestigious event brings together cancer researchers, clinicians, and industry experts from around the world to share groundbreaking insights. At EACR 2024, we will be showcasing our approaches in oncology, the next frontier for mRNA technology. Our team has been working tirelessly to advance our unique platform in this field, and we’re excited to share our findings with the scientific community. Read more about the event: https://2024.eacr.org/